Valence8 US LP Buys Shares of 17,495 Zura Bio Limited (NASDAQ:ZURA)

Valence8 US LP purchased a new position in shares of Zura Bio Limited (NASDAQ:ZURA) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 17,495 shares of the company’s stock, valued at approximately $71,000.

Several other large investors have also made changes to their positions in ZURA. Point72 Asset Management L.P. acquired a new stake in Zura Bio in the second quarter valued at about $8,446,000. Great Point Partners LLC boosted its stake in shares of Zura Bio by 68.3% in the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after purchasing an additional 1,884,501 shares in the last quarter. Armistice Capital LLC grew its holdings in shares of Zura Bio by 53.2% during the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after purchasing an additional 876,000 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Zura Bio by 51.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 291,807 shares of the company’s stock worth $1,185,000 after purchasing an additional 98,972 shares in the last quarter. Finally, Palumbo Wealth Management LLC bought a new position in Zura Bio in the 3rd quarter valued at approximately $156,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

Insider Buying and Selling

In related news, Director Someit Sidhu sold 51,728 shares of the company’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total transaction of $200,187.36. Following the sale, the director now owns 2,085,418 shares in the company, valued at $8,070,567.66. This represents a 2.42 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 22.10% of the stock is owned by insiders.

Zura Bio Price Performance

Shares of ZURA stock opened at $2.93 on Friday. Zura Bio Limited has a 1-year low of $2.00 and a 1-year high of $6.35. The stock has a 50-day moving average of $4.16 and a 200-day moving average of $4.08.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Research analysts expect that Zura Bio Limited will post -0.65 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. HC Wainwright reaffirmed a “neutral” rating and set a $5.00 target price on shares of Zura Bio in a research note on Monday. Piper Sandler reaffirmed an “overweight” rating and issued a $26.00 target price on shares of Zura Bio in a report on Thursday, September 19th. Leerink Partnrs upgraded Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th. Chardan Capital lowered their price objective on Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 8th. Finally, Leerink Partners initiated coverage on shares of Zura Bio in a report on Monday, November 4th. They issued an “outperform” rating and a $15.00 price objective for the company. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $15.80.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.